The landscape of T-cell engagers for the treatment of follicular lymphoma
Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to che...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412869 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850108129702838272 |
|---|---|
| author | Alfredo Rivas-Delgado Ivan Landego Lorenzo Falchi |
| author_facet | Alfredo Rivas-Delgado Ivan Landego Lorenzo Falchi |
| author_sort | Alfredo Rivas-Delgado |
| collection | DOAJ |
| description | Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies. |
| format | Article |
| id | doaj-art-e58a0910b16941e782316f10e9ee17bd |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-e58a0910b16941e782316f10e9ee17bd2025-08-20T02:38:26ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2412869The landscape of T-cell engagers for the treatment of follicular lymphomaAlfredo Rivas-Delgado0Ivan Landego1Lorenzo Falchi2Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, USADepartment of Internal Medicine, Max Rady Faculty of Health Sciences, Section of Medical Oncology and Hematology, University of Manitoba, Winnipeg, MB, CanadaDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, USAFollicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412869Bispecific antibodiesfollicular lymphomaimmunotherapyepcoritamabglofitamabmosunetuzumab |
| spellingShingle | Alfredo Rivas-Delgado Ivan Landego Lorenzo Falchi The landscape of T-cell engagers for the treatment of follicular lymphoma OncoImmunology Bispecific antibodies follicular lymphoma immunotherapy epcoritamab glofitamab mosunetuzumab |
| title | The landscape of T-cell engagers for the treatment of follicular lymphoma |
| title_full | The landscape of T-cell engagers for the treatment of follicular lymphoma |
| title_fullStr | The landscape of T-cell engagers for the treatment of follicular lymphoma |
| title_full_unstemmed | The landscape of T-cell engagers for the treatment of follicular lymphoma |
| title_short | The landscape of T-cell engagers for the treatment of follicular lymphoma |
| title_sort | landscape of t cell engagers for the treatment of follicular lymphoma |
| topic | Bispecific antibodies follicular lymphoma immunotherapy epcoritamab glofitamab mosunetuzumab |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412869 |
| work_keys_str_mv | AT alfredorivasdelgado thelandscapeoftcellengagersforthetreatmentoffollicularlymphoma AT ivanlandego thelandscapeoftcellengagersforthetreatmentoffollicularlymphoma AT lorenzofalchi thelandscapeoftcellengagersforthetreatmentoffollicularlymphoma AT alfredorivasdelgado landscapeoftcellengagersforthetreatmentoffollicularlymphoma AT ivanlandego landscapeoftcellengagersforthetreatmentoffollicularlymphoma AT lorenzofalchi landscapeoftcellengagersforthetreatmentoffollicularlymphoma |